Jasper Therapeutics, Inc. (JSPR) Dividend History

Jasper Therapeutics, Inc. (JSPR) is a biotechnology company focused on developing therapies for hematopoietic stem cell transplantation. The company's primary goal is to improve conditioning regimens and expand treatment options for patients with blood disorders, including sickle cell disease, thalassemia, and certain malignancies. Jasper applies its proprietary technologies to create targeted conditioning agents and stem cell therapies to enhance transplant safety and efficacy.

2200 Bridge Pkwy Suite #102, Redwood City, CA, 94065
Phone: (650) 549-1400
Website: https://www.jaspertherapeutics.com

Dividend History

Jasper Therapeutics, Inc. currently does not pay dividends

Company News

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Jasper Therapeutics presented updated clinical data from the Phase 1b/2a BEACON study and preclinical data on its antibody therapy briquilimab, which targets c-Kit to address mast cell-driven diseases. The data showed briquilimab was well-tolerated and demonstrated favorable safety and efficacy profiles, supporting its advancement into a registrational program for chronic spontaneous urticaria.

GlobeNewswire Inc.
Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

Jasper Therapeutics, a clinical-stage biotechnology company, announced a late-breaking oral presentation of data from its Phase 1b/2a BEACON study on briquilimab, a novel antibody therapy targeting c-Kit, at the 2025 AAD Annual Meeting. The presentation will focus on the rapid and clinically meaningful reduction in disease activity in adults with chronic spontaneous urticaria (CSU).

GlobeNewswire Inc.
Jasper Therapeutics to Present at Upcoming March Investor Conferences

Jasper Therapeutics, a clinical-stage biotechnology company, announced its participation in upcoming investor conferences in March 2025. The company is focused on developing briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell-driven diseases such as chronic spontaneous urticaria, chronic inducible urticaria, and asthma.

GlobeNewswire Inc.
Chronic Spontaneous Urticaria Market to Register Incremental Growth During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsight

The chronic spontaneous urticaria market is expected to grow due to increased disease prevalence, improved diagnosis, and the launch of new therapies. Key companies working on innovative treatments include Novartis, Sanofi, Regeneron, Celldex Therapeutics, Jasper Therapeutics, and others.

GlobeNewswire Inc.

Featured Companies: CLDX REGN
Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Jasper Therapeutics, a clinical-stage biotechnology company, announced upcoming presentations on its antibody therapy briquilimab at the AAAAI 2025 Annual Meeting. Briquilimab is being developed to address mast cell-driven diseases such as chronic spontaneous urticaria, chronic inducible urticaria, and asthma.

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 08:55:23 UTC